According to Catalyst Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0.39 B. In 2022 the company made a revenue of $0.21 B an increase over the years 2021 revenue that were of $0.14 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.39 B | 85.9% |
2022 | $0.21 B | 52.1% |
2021 | $0.14 B | 18.27% |
2020 | $0.11 B | 16.39% |
2019 | $0.10 B | 20361.27% |
2018 | $0.5 M | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | -100% |
2010 | $0.48 M | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 23,260.39% | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | 14,590.21% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $40.10 B | 9,972.48% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $1.24 B | 212.24% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $0.11 B | -70.46% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $2.41 B | 507.53% | ๐บ๐ธ USA |